Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2019

Open Access 01-12-2019 | Isoniazid | Case report

Development of active tuberculosis during treatment of head and neck carcinoma: a case series

Author: Mioko Matsuo

Published in: Journal of Medical Case Reports | Issue 1/2019

Login to get access

Abstract

Background

Patients with head and neck carcinoma are considered to be at high risk of developing tuberculosis, since the risk of morbidity due to tuberculosis in these patients is 2.86 to 16 times the risk in the general population.

Case presentation

This case series describes an 83-year-old Japanese man, a 60-year-old Japanese man, and a 69-year-old Japanese man who developed active pulmonary tuberculosis while being treated for head and neck carcinoma. Two had previously developed tuberculosis and were treated for more than 50 years, but no symptoms or imaging findings suggested tuberculosis onset in the patients at initiation of treatment for head and neck carcinoma. Initially, local radiotherapy was performed for all three patients. Chemotherapy was continued for two patients who had pulmonary metastasis since initial consultation. For the other patient, surgery was performed for recurrence. In all three cases, active tuberculosis infection was observed during maintenance chemotherapy or immediately following surgery.

Conclusions

Due to the high risk of developing tuberculosis, the possibility of prophylactic administration of anti-tuberculosis agents to patients with head and neck carcinoma should be investigated, although prophylactic administration is not a cost-effective option for all patients with head and neck carcinoma. However, if tuberculosis onset occurs, it leads to various problems; it has a major impact on not only patients with cancer but also various people in the social environment. In the future, it is essential to consider prophylactic administration in patients requiring long-term maintenance drug therapy, especially in those who are treated at out-patient chemotherapy clinics, where there are several patients with cancer with low disease resistance.
Literature
2.
go back to reference Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis. 2008;12:1352–64.PubMed Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis. 2008;12:1352–64.PubMed
3.
go back to reference American Thoracic Society & Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. 2000;49:1–51. American Thoracic Society & Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm. 2000;49:1–51.
4.
go back to reference Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:635–44.CrossRef Cheng MP, Abou Chakra CN, Yansouni CP, Cnossen S, Shrier I, Menzies D, et al. Risk of active tuberculosis in patients with cancer: a systematic review and meta-analysis. Clin Infect Dis. 2017;64:635–44.CrossRef
6.
go back to reference Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging. 1997;12:41–6.CrossRef Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging. 1997;12:41–6.CrossRef
7.
go back to reference Nishiike S, Osaki Y, Uno M, Irifune M, Aihara T, Harada T. Active pulmonary tuberculosis accompanying head and neck carcinomas: clinical aspects of 9 cases. Jibirinsho. 2008;101:549–53. (Article in Japanese) Nishiike S, Osaki Y, Uno M, Irifune M, Aihara T, Harada T. Active pulmonary tuberculosis accompanying head and neck carcinomas: clinical aspects of 9 cases. Jibirinsho. 2008;101:549–53. (Article in Japanese)
8.
go back to reference Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck carcinoma. N Engl J Med. 2008;359:1116–27.CrossRef Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck carcinoma. N Engl J Med. 2008;359:1116–27.CrossRef
9.
go back to reference Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.CrossRef Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.CrossRef
10.
go back to reference Bailey WC, Albert RK, Davidson PT, Farer LS, Glassroth J, Kendig E Jr, et al. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis. 1983;127:790–6. Bailey WC, Albert RK, Davidson PT, Farer LS, Glassroth J, Kendig E Jr, et al. Treatment of tuberculosis and other mycobacterial diseases. Am Rev Respir Dis. 1983;127:790–6.
11.
go back to reference Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592–5.CrossRef Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592–5.CrossRef
Metadata
Title
Development of active tuberculosis during treatment of head and neck carcinoma: a case series
Author
Mioko Matsuo
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2019
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-019-2055-2

Other articles of this Issue 1/2019

Journal of Medical Case Reports 1/2019 Go to the issue